Skip to content

Microvascular Function in Primary Aldosteronism

Microvascular Function in Patients With Primary Aldosteronism and Essential Hypertension

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02096939
Enrollment
0
Registered
2014-03-26
Start date
2014-09-30
Completion date
2016-04-30
Last updated
2015-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension, Primary Aldosteronism

Brief summary

Patients with primary aldosteronism, which is the most prevalent form of secondary hypertension, have an increased rate of cardiovascular events, compared to patients with essential hypertension, even with equal severity of hypertension. This might be partially attributed to the association of increased aldosterone levels with insulin resistance. How this relation can be explained from a pathophysiological point of view, is insufficiently established. Recently, microvascular dysfunction has been proposed as a link between insulin resistance and hypertension. Loss of NO-mediated vasodilation is an important feature of microvascular dysfunction; in addition, an impaired insulin-mediated microvascular NO production has been suggested to underlie the reduction in insulin-stimulated glucose disposal that is characteristic of insulin-resistant states. Increased aldosterone levels are not only associated with insulin resistance, but also with endothelial dysfunction. In addition, they interfere with the vascular effects of insulin. Therefore, the investigators hypothesize that in patients with primary aldosteronism, increased aldosterone levels induce microvascular dysfunction through reduction of NO-availability, which contributes to the development of insulin resistance, and of hypertension, in addition to the sodium-retaining effects of aldosterone.

Interventions

PROCEDUREAdrenal extirpation

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Patients with primary aldosteronism * Age 18-70 years * Confirmed diagnosis of primary aldosteronism * Serum potassium \> 3.5 mmol/L with or without supplementation Patients with essential hypertension * Age 18-70 years * Secondary causes of hypertension excluded

Exclusion criteria

* Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death) * Diabetes mellitus * Unstable or severe pulmonary disease * Inflammatory diseases * Alcohol use \> 2 U/day (women) / \> 3 U/day (men) * (Frequent) use of acetylsalicylic acid, NSAID's, dipyridamole and corticosteroids * eGFR \< 60 mL/min * Impairment of hepatic function * Pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Microvascular recruitment in skeletal muscle during hyperinsulinaemiaBaseline

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026